Catabasis Pharmaceuticals, which is developing combination therapies for rare diseases based on its drug delivery platform, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering.
The Cambridge, MA-based company, which was founded in 2008, plans to list on the NASDAQ under the symbol CATB. Catabasis Pharmaceuticals initially filed confidentially on January 23, 2015. Citi and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
